Crossmark

Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

Crossref DOI link: https://doi.org/10.1016/j.medcle.2024.05.002

Published Print: 2024-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Romero-Bogado, Liz

Steiner, Martina

Vasallo, Israel John Thuissard

Vázquez, Cristina Andreu

Navío, Teresa

Muñoz-Fernández, Santiago
License Information

Text and Data Mining valid from 2024-05-01

Text and Data Mining valid from 2024-05-01

stm-asf valid from 2024-05-01

stm-asf valid from 2024-05-01

stm-asf valid from 2024-05-01

stm-asf valid from 2024-05-01

stm-asf valid from 2024-05-01
More Information

This article is maintained by: Elsevier

Article Title: Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2024.05.002

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2023.12.011

Content Type: article

Copyright: © 2024 Elsevier España, S.L.U. All rights reserved.